Journal: Journal of Immunology Research

Article Title: Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

doi: 10.1155/2017/1423683

Figure Lengend Snippet: Plasma levels of HMGB1 during peptide vaccination. Plasma HMGB1 levels of pre- and post-1st cycle vaccination samples of the total 39 cases (a), the 21 serous-type cases (b), and the 18 non-serous-type cases (c) are shown. ns: Not significant.

Article Snippet: The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by t -test and chi-square test.

Techniques: Clinical Proteomics

Journal: Journal of Immunology Research

Article Title: Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

doi: 10.1155/2017/1423683

Figure Lengend Snippet: The relationship between plasma HMGB1 levels and overall survival (OS) was analyzed by Kaplan-Meier plot analysis. Patients ( n = 39) were divided into high and low plasma HMGB1 groups based on the (a) pre- and (b) postvaccination levels, and the correlation between these subgroups and OS was analyzed. (c) Patients ( n = 39) were also divided into decreased and not-decreased groups based on the changes of plasma HMGB1 between the prevaccination and postvaccination samples, and the relation between these subgroups and OS was plotted.

Article Snippet: The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by t -test and chi-square test.

Techniques: Clinical Proteomics

Journal: Journal of Immunology Research

Article Title: Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

doi: 10.1155/2017/1423683

Figure Lengend Snippet: HMGB1 and other biomarkers of patients with ovarian cancer treated with peptide vaccination † .

Article Snippet: The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by t -test and chi-square test.

Techniques:

Journal: Journal of Immunology Research

Article Title: Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

doi: 10.1155/2017/1423683

Figure Lengend Snippet: Correlations between postvaccination plasma HMGB1 levels and postvaccination levels of MDSC frequency, SAA, CRP, or IL-6 were analyzed by scatter plot.

Article Snippet: The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by t -test and chi-square test.

Techniques: Clinical Proteomics

Journal: Journal of Immunology Research

Article Title: Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer

doi: 10.1155/2017/1423683

Figure Lengend Snippet: Comparison of HMGB1 and other biomarkers.

Article Snippet: The comparisons between plasma HMGB1 levels and other biomarkers were analyzed by t -test and chi-square test.

Techniques: Comparison

Journal: PLoS ONE

Article Title: Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

doi: 10.1371/journal.pone.0178404

Figure Lengend Snippet: (a) Comparison of plasma levels of HMGB1 between pAPS, APA + SLE, APS + SLE patients and HCs. (b) Comparison of plasma levels of HMGB1 between SLE patients with and without disease flares. (c) Comparison of plasma levels of sRAGE between pAPS, APA + SLE, APS + SLE patients and HCs. (d) Comparison of plasma levels of sRAGE between SLE patients with and without disease flares. P values of < 0.008 were regarded as statistically significant for multiple comparisons. APA, antiphospholipid antibody; HC, healthy control; HMGB1, high-mobility group box 1; pAPS, primary antiphospholipid syndrome; SLE, systemic lupus erythematosus; sRAGE, soluble receptor for advanced glycation end products.

Article Snippet: Plasma levels of HMGB1 were determined using sandwich ELISA kits (Chondrex, Redmond, WA) in accordance with the manufacturer’s instructions.

Techniques:

Journal: PLoS ONE

Article Title: Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

doi: 10.1371/journal.pone.0178404

Figure Lengend Snippet: (a) Poor correlation of ELISA with Western blot in the measurement of plasma levels of HMGB1 in both pAPS patients and HCs. (b) Comparison of plasma levels of HMGB1 between pAPS patients and HCs. Band intensities were quantified by ImageJ. HC, healthy control; HMGB1, high-mobility group box 1; pAPS, primary antiphospholipid syndrome; WB, Western blot.

Article Snippet: Plasma levels of HMGB1 were determined using sandwich ELISA kits (Chondrex, Redmond, WA) in accordance with the manufacturer’s instructions.

Techniques: Enzyme-linked Immunosorbent Assay, Western Blot

Journal: PLoS ONE

Article Title: Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

doi: 10.1371/journal.pone.0178404

Figure Lengend Snippet: The relationships between subgroups of patients and log-transformed plasma levels of HMGB1 or sRAGE in a multivariate linear regression model (R 2 = 0.04 for plasma HMGB1; R 2 = 0.19 for plasma sRAGE).

Article Snippet: Plasma levels of HMGB1 were determined using sandwich ELISA kits (Chondrex, Redmond, WA) in accordance with the manufacturer’s instructions.

Techniques:

Journal: PLoS ONE

Article Title: Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

doi: 10.1371/journal.pone.0178404

Figure Lengend Snippet: (a) Correlation between plasma levels of HMGB1 and serum ACA IgG titers; (b) Correlation between plasma levels of sRAGE and serum ACA IgG titers; (c) Correlation between plasma levels of HMGB1 and serum ACA IgM titers; (d) Correlation between plasma levels of sRAGE and serum ACA IgM titers. Correlation analyses were performed using Spearman’s rank correlation test. ACA: anticardiolipin antibodies; HMGB1, high-mobility group box 1; sRAGE, soluble receptor for advanced glycation end products.

Article Snippet: Plasma levels of HMGB1 were determined using sandwich ELISA kits (Chondrex, Redmond, WA) in accordance with the manufacturer’s instructions.

Techniques:

Journal: PLoS ONE

Article Title: Plasma levels of high-mobility group box 1 and soluble receptor for advanced glycation end products in primary antiphospholipid antibody syndrome patients

doi: 10.1371/journal.pone.0178404

Figure Lengend Snippet: (a) Correlation between plasma levels of HMGB1 and sRAGE; (b) Correlation between plasma levels of HMGB1 and serum anti-dsDNA; (c) Correlation between plasma levels of HMGB1 and serum C3; (d) Correlation between plasma levels of HMGB1 and serum C4; (e) Correlation between plasma levels of HMGB1 and SLEDAI; (f) Correlation between plasma levels of sRAGE and serum anti-dsDNA; (g) Correlation between plasma levels of sRAGE and serum C3; (h) Correlation between plasma levels of sRAGE and serum C4; (i) Correlation between plasma levels of sRAGE and SLEDAI. Correlation analyses were performed using Spearman’s rank correlation test. a One APS + SLE patient did not receive anti-dsDNA, C3 and C4 examinations. APS, antiphospholipid syndrome; C3, complement 3; C4, complement 4; anti-dsDNA, anti-double-stranded DNA antibody; HMGB1, high-mobility group box 1; SLE, systemic lupus erythemtosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; sRAGE, soluble receptor for advanced glycation end products.

Article Snippet: Plasma levels of HMGB1 were determined using sandwich ELISA kits (Chondrex, Redmond, WA) in accordance with the manufacturer’s instructions.

Techniques: Activity Assay

Journal: Toxics

Article Title: HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.

doi: 10.3390/toxics13060448

Figure Lengend Snippet: Figure 1. Elevated HMGB1 Expression in MM cell lines and xenograft models. (A) Relative HMGB1 mRNA levels in MM cell lines (NCI-H2452 and MSTO-211H) compared to normal mesothelial cells (MeT-5A), determined by quantitative real-time PCR. (B) Representative Western blot images showing HMGB1 protein expression in MM cell lines (NCI-H2452 and MSTO-211H) and normal mesothelial cells (MeT-5A). (C) Representative images of tumors from the MM xenograft model established by subcutaneous injection of MSTO-211H cells into BALB/c nude mice. (D) Plasma HMGB1 levels measured by ELISA in xenograft model mice. **, p < 0.01; ***, p < 0.001.

Article Snippet: Plasma HMGB1 levels were quantified using a Mouse HMGB1 ELISA kit (Wuhan Huamei Cusabio Biotech Co., Wuhan, China).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Western Blot, Injection, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

Journal: Toxics

Article Title: HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.

doi: 10.3390/toxics13060448

Figure Lengend Snippet: Figure 3. Effect of HMGB1 silencing on MM cell migration and invasion. Scratch wound healing assays showing the migration of MSTO-211H (A) and NCI-H2452 cells (B) treated with blank control,

Article Snippet: Plasma HMGB1 levels were quantified using a Mouse HMGB1 ELISA kit (Wuhan Huamei Cusabio Biotech Co., Wuhan, China).

Techniques: Migration, Control

Journal: Toxics

Article Title: HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.

doi: 10.3390/toxics13060448

Figure Lengend Snippet: Figure 4. Effect of HMGB1 silencing and EP treatment on cell cycle arrest and apoptosis. Comparison of apoptosis in MSTO-211H (A) and NCI-H2452 (B) cells treated with blank control, siRNA control, and HMGB1 siRNA. Cell cycle distribution in MSTO-211H (C) and NCI-H2452 (D) cells treated with 0, 2.5, 5, and 10 mM EP. Apoptosis analysis of MSTO-211H (E) and NCI-H2452 (F) cells treated with 0, 2.5, 5, 10, and 20 mM EP. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control group; # p < 0.05, ## p < 0.01 vs. siRNA control group.

Article Snippet: Plasma HMGB1 levels were quantified using a Mouse HMGB1 ELISA kit (Wuhan Huamei Cusabio Biotech Co., Wuhan, China).

Techniques: Comparison, Control

Journal: Toxics

Article Title: HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.

doi: 10.3390/toxics13060448

Figure Lengend Snippet: Figure 5. Effect of TAK-242 and TLR4 siRNA treatment on HMGB1-TLR4 signaling pathway in MM cells. The mRNA expression of key molecules in the HMGB1-TLR4 signaling axis in MSTO-211H (A) and NCI-H2452 (B) cells treated with 0 and 100 µM TAK-242. The mRNA expression of key molecules in the HMGB1-TLR4 signaling axis in MSTO-211H (C) and NCI-H2452 (D) cells treated with TLR4 siRNA. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. control group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. siRNA control group.

Article Snippet: Plasma HMGB1 levels were quantified using a Mouse HMGB1 ELISA kit (Wuhan Huamei Cusabio Biotech Co., Wuhan, China).

Techniques: Expressing, Control

Journal: Toxics

Article Title: HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.

doi: 10.3390/toxics13060448

Figure Lengend Snippet: Figure 6. Effect of EP and TAK-242 treatment on MM xenograft model in vivo. (A) Representative images of mice and tumors after treatment treated with PBS, EP, or TAK-242. (B) Changes in body weight of mice over time after PBS, EP, or TAK-242 treatment. (C) Tumor volume measurements over time in mice treated with PBS, EP, or TAK-242. (D) Tumor weights in mice treated with PBS, EP, or TAK-242. (E) H&E staining of tumor tissues from PBS, EP, and TAK-242 treated groups. (F) Immunohistochemical staining showing HMGB1 expression in tumor tissues from the three treatment groups. (G) Plasma HMGB1 levels measured by ELISA in the three treatment groups. * p < 0.05.

Article Snippet: Plasma HMGB1 levels were quantified using a Mouse HMGB1 ELISA kit (Wuhan Huamei Cusabio Biotech Co., Wuhan, China).

Techniques: In Vivo, Staining, Immunohistochemical staining, Expressing, Clinical Proteomics, Enzyme-linked Immunosorbent Assay